Shoulder Innovations Inc

Shoulder Innovations Inc(SI)の株式分析

$21.160

-0.110 (-0.52%)終値時点

Loading chart…
High
22.000
Open
21.340
VWAP
21.40
Vol
51.96K
Mkt Cap
Low
21.050
Amount
1.11M
EV/EBITDA, TTM
0.00

Shoulder Innovations, Inc. is a commercial-stage medical technology company focused on transforming the shoulder surgical care market. The Company offers advanced implant systems for shoulder arthroplasty. These systems are a core element of its ecosystem, designed to improve the core components of shoulder surgical care, preoperative planning, implant design and procedural efficiency, to benefit each stakeholder in the care chain. Its ecosystem is also comprised of enabling technologies, instrument systems, specialized support and surgeon-to-surgeon collaboration. Its advanced implants are comprised of its aTSA and rTSA systems, which are designed to address the needs of patients and surgeons, and include various, specifically designed components capable of an array of system configurations to facilitate different modes of operation (anatomic or reverse). Its InSet Glenoid technology serves as the foundation for its advanced implant systems and includes a novel InSet design.

AI analysis of Shoulder Innovations Inc (SI)

buy

Shoulder Innovations Inc is a good buy right now, primarily driven by its recent revenue growth of 47.25% year-to-date and a strong gross margin of 78.26% in Q2 2026. The stock has shown resilience with a recent price of $21.16, and analysts have set a price target of $28, suggesting a potential upside of 32.5%. However, investors should be cautious of the company's recent net income fluctuations, particularly the net loss of $10.15 million in Q2 2026, which poses a risk to profitability.

バリュエーション指標

The current forward P/E ratio for Shoulder Innovations Inc (SI) is 0.00, compared to its 5-year average forward P/E of -9.14.

Forward P/E

Strongly Overvalued
5Y Average P/E
-9.14
Current P/E
0.00
割高
-7.51
割安
-10.76

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
-12.14
Current EV/EBITDA
0.00
割高
-8.35
割安
-15.93

Forward P/S

Fair
5Y Average P/S
4.77
Current P/S
5.01
割高
5.79
割安
3.76

イベントタイムライン

2026-08-10 (ET)

07:30:00

Shoulder Innovations Appoints Jon Osborne as Chief Commercial Officer

2026-08-07 (ET)

16:30:00

Shoulder Innovations Files $300M Mixed Securities Shelf

2026-08-06 (ET)

17:01:00

Shoulder Innovations Q2 Revenue $17.2M Beats Expectations

2026-05-13 (ET)

16:20:00

Shoulder Innovations Q1 Revenue $16.71M Beats Expectations

2026-03-10 (ET)

16:30:00

Shoulder Innovations Q4 Revenue $14.4M Beats Expectations

ニュース

SI FAQ — answered by Alphio AI

Shoulder Innovations, Inc. is a commercial-stage medical technology company focused on transforming the shoulder surgical care market. The Company offers advanced implant systems for shoulder arthroplasty. These systems are a core element of its ecosystem, designed to improve the core components of shoulder surgical care, preoperative planning, implant design and procedural efficiency, to benefit each stakeholder in the care chain. Its ecosystem is also comprised of enabling technologies, instrument systems, specialized support and surgeon-to-surgeon collaboration. Its advanced implants are comprised of its aTSA and rTSA systems, which are designed to address the needs of patients and surgeons, and include various, specifically designed components capable of an array of system configurations to facilitate different modes of operation (anatomic or reverse). Its InSet Glenoid technology serves as the foundation for its advanced implant systems and includes a novel InSet design. It operates in the Healthcare sector.

Shoulder Innovations Inc is a good buy right now, primarily driven by its recent revenue growth of 47.25% year-to-date and a strong gross margin of 78.26% in Q2 2026. The stock has shown resilience with a recent price of $21.16, and analysts have set a price target of $28, suggesting a potential upside of 32.5%. However, investors should be cautious of the company's recent net income fluctuations, particularly the net loss of $10.15 million in Q2 2026, which poses a risk to profitability.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める